Additional data from GenSight’s REVERSE phase 3 clinical trial of GS010 for the treatment of Leber hereditary optic neuropathy show the single intravitreal injection met some secondary endpoints, according to a press release.
Topline results, which were reported in April, showed the treatment did not meet its primary endpoint of +15 ETDRS letters difference compared with sham-treated eyes but did meet secondary endpoints as defined by spectral-domain OCT parameters.
On further analysis, some secondary endpoints did not have significant or meaningful changes. Contrast sensitivity, however,
Uncategorized